Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether low level laser therapy can help the recovery process for the procedure of liposuction of the thighs, hips and stomach.
The Erchonia EML Laser is designed to administer low level laser therapy (LLLT). It has been hypothesized that LLLT may reduce pain and promote nerve regeneration through the speculated anti-inflammatory and immune enhancement properties of the therapy. Prior research has indicated LLLT to be a potentially safe and effective means of reducing pain. This clinical study was designed to evaluate the potential of the Erchonia EML Laser in offering a novel means of delivering LLLT to reduce pain and enhance healing following liposuction.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| placebo laser | Placebo Comparator | inactive light on the laser device. |
|
| Erchonia (R) LipoLASER PL | Active Comparator | The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser | Device | The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated. |
| Measure | Description | Time Frame |
|---|---|---|
| Subject self-reported Degree of Pain rating on the standardized 0-100 Visual Analogue Scale (VAS) at 24 hours post-surgery. | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Ease of the process of fat extraction during the liposuction procedure | immediately post surgery | |
| Emulsification (consistency) of extracted fat | immediately post surgery | |
Not provided
Inclusion Criteria: There were separate inclusion criteria for both the liposuction and the clinical study components of the study.
INCLUSION CRITERIA FOR THE LIPOSUCTION PROCEDURE
Prior to partaking in the clinical study qualification evaluation, an individual must have already:
INCLUSION CRITERIA FOR THE CLINICAL STUDY
EXCLUSION CRITERIA
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert F Jackson, MD, FACS | Principal Investigator | |
| Gregory Roche, DO | Principal Investigator | |
| Kimberly Butterwick, MD | Principal Investigator |
Not provided
Not provided
| Label | URL |
|---|---|
| FDA 510(k) clearance listing resulting from the outcome of this clinical study | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Erchonia(R) LipoLASER PL | Device |
|
| Amount of time spent by volume of fat removed |
| Immediately post surgery |
| Degree of swelling at the surgical site | 7 days post surgery |
| Subject self-reported degree of post-surgical pain | 7, 14 and 28 days post surgery |
| Use of recovery pain medication | Through the 1st 7 post-surgical days |